Back

ESMO Plenary Feb 2024 - ESMO Virtual Plenary with AACR Expert Commentary: February 2024

Feb 15 - Feb 16, 2024 | LuganoSwitzerland

LARVOL is not affiliated with ESMO Virtual Plenary with AACR Expert Commentary: February 2024 and all trademarks, logos, and brand names are property of their respective owners

Top Trials
Condition
Product
MOA
Trial Name/ID

Showing 1 titles linked to Trials

RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

1 Twitter Reactions